Form 4: Zimmer Biomet Director Accrues Phantom Stock Units

Zimmer Biomet Holdings, Inc. Director Sreelakshmi Kolli accrued 159.276 phantom stock units, increasing her beneficial ownership to 5,393.594 units.

Summary

• Director Sreelakshmi Kolli acquired 159.276 phantom stock units on September 30, 2025.
• These units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• Following this transaction, Kolli beneficially owns a total of 5,393.594 phantom stock units.
• The phantom stock units convert to common stock on a 1-for-1 basis.
• The units are to be settled in shares of Company common stock within sixty days after Kolli's cessation of service as a Director.
• The total beneficial ownership includes 13.119 phantom stock units accrued on July 31, 2025, through the dividend reinvestment provision of the Deferred Compensation Plan.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. It's a routine compensation event, indicating continued director involvement and alignment, but not a significant market-moving event.

Positives

• Increased alignment of a director's interests with shareholders through additional equity-linked compensation.
• Accrual of units under a deferred compensation plan indicates a structured and standard approach to director compensation.

Negatives

• No direct cash investment by the director in this specific transaction, as units were accrued rather than purchased for cash.

Future Outlook

Phantom stock units are scheduled to be settled in shares of company common stock within sixty days after the reporting person's cessation of service as a Director.

Industry Context

This Form 4 filing reports a routine equity compensation accrual for a director, which is a common practice in the medical device industry and across publicly traded companies to align director incentives with shareholder value. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• The accrual of phantom stock units as part of a deferred compensation plan for non-employee directors is a standard practice in corporate governance across various industries, including medical devices.
• This method of compensation is designed to align director interests with long-term shareholder value without requiring immediate cash outlay from the director.
• Specific comparable companies or projects are not detailed in this filing, as it focuses solely on an individual director's transaction.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholder value through equity-linked compensation.

Next Steps

• Settlement of phantom stock units into common stock shares within sixty days after Sreelakshmi Kolli ceases service as a Director.

Key Dates

Recommendation

This Form 4 filing details a routine accrual of phantom stock units by a director as part of their compensation plan. It signifies ongoing director alignment with shareholder interests but does not present new information that would fundamentally alter the investment thesis for Zimmer Biomet Holdings, Inc. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Zimmer Biomet Holdings, ZBH, Sreelakshmi Kolli, Form 4, Insider Transaction, Phantom Stock Units, Director Compensation, Equity Compensation, Deferred Compensation